
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

HaystackAnalytics unveils worldâ??s first comprehensive diagnostic test to detect bacterial, fungal, and respiratory RNA viruses

15 October 2024 | News

World's first company to introduce a comprehensive genomics-based diagnostic test for infectious diseases



Mumbai-based startup HaystackAnalytics has announced a significant milestone in precision medicine by expanding its infexn™ test using Next Generation Sequencing (NGS).

The existing infexn™ test using NGS which has been in use for the comprehensive detection of bacteria, fungi and antimicrobial resistance (AMR) in a single test, has now been upgraded to also detect respiratory RNA viruses.

Thus, by testing respiratory samples, such as VTM, BAL, etc. using the infexn™ NGS test, clinicians are further enabled towards antimicrobial stewardship (AMSP), wherein they may not choose a specific test for a specific suspected infection. Instead a single infexn™ - NGS test can screen for major RNA viruses, all bacterial and fungal human pathogens, and AMR.

While there are very few well established antiviral treatment options, clinicians worldwide can make safer choices when supported by comprehensive diagnostic methods. The expansion of the scope of the infexn™ test using NGS, to include the detection of major respiratory RNA viruses, is a step in this direction of hypothesis free, universal infectious diseases testing paradigm.

The next-generation sequencing test, infexn™, developed by HaystackAnalytics, is a genomics-based test capable of detecting pan-bacterial, pan-fungal, and now respiratory viral infections, along with identifying relevant rare and difficult-to-culture organisms, all within 24 hours. Developed in India and designed for global application, infexn™ using NGS emerges as the preferred test for detecting deadly infectious diseases. It holds the potential to promptly identify infections, empowering the healthcare ecosystem with advanced diagnostics to provide a customised care regime for patients. In the myriad of emerging infectious agents, infexn™ using NGS has now evolved into a versatile diagnostic tool for doctors.